<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00648063</url>
  </required_header>
  <id_info>
    <org_study_id>LETR-05122</org_study_id>
    <nct_id>NCT00648063</nct_id>
  </id_info>
  <brief_title>Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg</brief_title>
  <official_title>Single-Dose Fasting Bioequivalence Study of Letrozole Tablets (2.5 mg; Mylan) and Femara® Tablets (2.5 mg; Novartis) in Healthy Postmenopausal Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mylan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate the bioequivalence of Mylan's letrozole 2.5 mg
      tablets to Novartis' Femara® 2.5 mg tablets following a single, oral 2.5 mg (1 x 2.5 mg) dose
      administered under fasting conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data.</measure>
    <time_frame>Blood collections through 216 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole Tablets 2.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Femara® Tablets 2.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole Tablets 2.5 mg</intervention_name>
    <description>2.5mg, single dose fasting</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Femara® Tablets 2.5 mg</intervention_name>
    <description>2.5mg, single dose fasting</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 40 years or older.

          2. Sex: Females only.

          3. Weight: At least 52 kg (115 lbs) and within 30% of Ideal Body Weight (IBW), as
             referenced by the Table of &quot;&quot;Desirable Weights of Adults&quot;&quot; from Metropolitan Life
             Insurance Company, 1999 (See Part II: ADMINISTRATIVE ASPECTS OF HUMAN BIOAVAILABILITY
             PROTOCOLS).

          4. Absence of menses for one year for postmenopausal subjects, or at least 6 weeks for
             oophorectomized subjects. (For oophorectomized subjects, an operative report
             documenting bilateral oophorectomy and surgical pathology report documenting the
             absence of malignant disease.)

          5. Baseline FSH and 17β-estradiol serum levels consistent with postmenopausal status
             confirmed within 72 hours of initiation of study medication (FSH greater than or equal
             to 40 mIU/mL; 17β-estradiol less than or equal to 31 pg/mL).

          6. All subjects should be judged normal and healthy during a pre-study medical evaluation
             (physical examination, laboratory evaluation, 12-lead ECG, Hepatitis B, Hepatitis C
             and HIV tests, and urine drug screen including amphetamine, barbiturates,
             benzodiazepines, cannabinoid, cocaine, opiates, phencyclidine, and methadone)
             performed within 21 days of the initial dose of study medication.

          7. The physical examination shall include pelvic and breast exams.

               1. Pelvic findings should be consistent with hypoestrogenemia.

               2. A mammogram will be required if not performed within the last 12 months.

               3. A Papanicolaou (&quot;Pap&quot;) smear will be required on subjects with an intact uterus
                  and cervix if not performed within the last 6 months.

        Exclusion Criteria:

          1. Institutionalized subjects will not be used.

          2. Social Habits:

               1. Use of any tobacco-containing products within 1 year of start of study.

               2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage
                  within the 48 hours prior to the initial dose of study medication.

               3. Ingestion of any vitamins or herbal products within 7 days prior to the initial
                  dose of the study medication.

               4. Any recent, significant change in dietary or exercise habits.

               5. A positive test for any drug included in the urine drug screen.

               6. History of drug and/or alcohol abuse.

          3. Medications:

               1. Use of any prescription or over-the-counter (OTC) medications within the 14 days
                  prior to the initial dose of study medication.

               2. Use of any medication known to alter hepatic enzyme activity within 28 days prior
                  to the initial dose of study medication.

               3. Use hormonal replacement therapy within 3 months prior to the initial dose of
                  study medication.

          4. Diseases:

               1. History of any significant chronic disease such as (but not limited to): 1.
                  Thrombotic disorders. 2. Coronary artery or cerebrovascular disease. 3. Liver,
                  kidney or gallbladder dysfunction/disorder(s). 4. Diabetes or any other
                  endocrinological disease. 5. Estrogen-dependent neoplasia. 6. Postmenopausal
                  uterine bleeding. 7. Endometrial hyperplasia.

               2. Acute illness at the time of either the pre-study medical evaluation or dosing.

               3. A positive HIV, Hepatitis B, or Hepatitis C test.

          5. Abnormal and clinically significant laboratory test results:

               1. Clinically significant deviation from the Guide to Clinically Relevant
                  Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).

               2. Abnormal and clinically relevant ECG tracing.

          6. Donation or loss of a significant volume of blood or plasma (&gt; 450 mL) within 28 days
             prior to the initial dose of study medication.

          7. Subjects who have received an investigational drug within 30 days prior to the initial
             dose of study medication.

          8. Allergy or hypersensitivity to letrozole, any of the inactive ingredients.

          9. History of difficulties in swallowing, or any gastrointestinal disease which could
             affect the drug absorption.

         10. Consumption of grapefruit or grapefruit containing products within 7 days of drug
             administration.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Galitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC International</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC International</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mpibiostudies.com</url>
    <description>Mylan Pharmaceuticals Inc. - Clinical Trial Results</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Recalls, Market Withdrawals and Safety Alerts</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/Enforce.html</url>
    <description>FDA Enforcement Report Index</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Medwatch, FDA Safety Information and Adverse Event Reporting Program</description>
  </link>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>November 30, 2009</last_update_submitted>
  <last_update_submitted_qc>November 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Wayne Talton</name_title>
    <organization>Mylan Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

